Inclusion Criteria:

1. Written informed consent,

2. Histologically confirmed stage M1a or M1b NSCLC,

3. Aged over 18 years old,

4. Measurable disease,

5. Life expectancy of at least 12 weeks,

6. No prior chemotherapy or target therapy,

7. No brain metastases or spinal cord compression,

8. Less than 10% body weight loss,

9. ECOG performance status 0-2,

10. Adequate vital organ function (haematological, renal, hepatic, etc).

11. Enough tissue for detection of BRCA1 and RRM1 expression.

Exclusion Criteria:

1. Prior systemic cytotoxic chemotherapy or EGFR TKI therapy,

2. Positive pregnancy test,

3. Another active malignancy, other than superficial basal cell and squamous cell or
carcinoma in situ of the cervix, within the last 5 years,

4. Patients with brain metastases or spinal cord compression,

5. Allergy to gemcitabine, cisplatin, docetaxel, CPT-11,

6. Any unstable systemic disease including active infection,

7. No enough tissue for detection of BRCA1 and RRM1